Get regular updates to your inbox.
A Phase 2 trial of ZZ Biotech’s investigational therapy 3K3A-APC in people with amyotrophic lateral sclerosis (ALS) has started dosing patients at its single site in Australia, the company announced in a press release. The open-label trial (NCT05039268), underway at the Macquarie University in Sydney, aims to evaluate…
Read more
While it’s long been believed that the death of motor neurons in the spinal cord is the main cause of amyotrophic lateral sclerosis (ALS), new research suggests that degeneration of motor neurons in the brain takes place independently and may also contribute to the disease. The study’s work in…
CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), showed consistent clinical benefits in patients with both limb and bulbar onset disease, according to new analyses of RESCUE-ALS Phase 2 clinical trial data. In particular, the treatment significantly extended the time to disease progression —…
When Leah Stavenhagen was 27, she was living in Paris and traveling through Europe. But an amyotrophic lateral sclerosis (ALS) diagnosis forced her to give up her job as a consultant with Ernst & Young and dashed her dreams of continuing to work abroad. At the time, she seemed…
Columnist Rick Jobus accepts a writing challenge and shares several appropriate ALS metaphors he’s formulated over the years.
Visit the ALS News Today forums to connect with others in the ALS community.
Becoming educated and informed about ALS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ALS journey.
There is no cure for ALS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
